Adalimumab dose escalation and dose de-escalation success rate and predictors in a large national cohort of Crohn's patients

Abstract

In this study real life nationwide cohort of Crohn's patients treated with adalimumab dose escalation was needed in 34% and was successful in 67%. Dose de-escalation was attempted in 54% and was successful in 63%. Overall 71% of patients maintained long term response on adalimumab.